Cargando…
Case Report: Good cardiac tolerance to Toripalimab in a CVD patient with oral melanoma
Primary oral melanoma is extremely rare, and the prognosis is very poor. With the development of immunotherapy, melanoma’s treatment landscape changed dramatically. Toripalimab, a recombinant programmed death receptor 1 (PD-1) monoclonal antibody, has been approved as second-line therapy for metasta...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376878/ https://www.ncbi.nlm.nih.gov/pubmed/35979233 http://dx.doi.org/10.3389/fphar.2022.890546 |